CorMedix Inc
CRMD
查看详细走势图
7.690USD
+0.340+4.63%
收盘 02/06, 16:00（美东）报价延迟15分钟
602.50M总市值
3.24市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+4.63%
5天
-0.90%
1月
-31.15%
6月
-28.86%
今年开始到现在
-33.88%
1年
-24.31%
查看详细走势图
TradingKey CorMedix Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
CorMedix Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名58/159位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价16.14。中期看，股价处于下降通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
CorMedix Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
CorMedix Inc亮点
亮点风险
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
业绩高增长
公司营业收入稳步增长，连续3年增长66363.08%
业绩增长期
公司处于发展阶段，最新年度总收入43.47M美元
估值高估
公司最新PE估值3.24，处于3年历史高位
机构加仓
最新机构持股43.86M股，环比增加0.02%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值6.95K
活跃度增加
近期活跃度增加，过去20天平均换手率2.50
分析师目标
根据
7
位分析师
买入
评级
16.143
目标均价
+105.90%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
CorMedix Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
CorMedix Inc简介
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
公司代码CRMD
公司CorMedix Inc
CEOTodisco (Joseph)
网址https://cormedix.com/
相关品种
